Trial Profile
A randomised, double blind phase I/II trial to investigate efficacy, immunogenicity and safety of intradermally administered BI 1361849 (CV9202) plus afatinib versus placebo plus afatinib as first-line treatment for patients with stage IV adenocarcinoma of the lung harbouring common EGFR mutations.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 12 Apr 2022
Price :
$35
*